NewEdge Wealth LLC Takes Position in Elevance Health, Inc. $ELV

Posted by George Bondi on May 15th, 2026

NewEdge Wealth LLC purchased a new position in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 2,684 shares of the company’s stock, valued at approximately $941,000.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Murphy Middleton Hinkle & Parker Inc. bought a new position in Elevance Health in the 4th quarter valued at $5,941,000. Evergreen Wealth Management LLC raised its position in shares of Elevance Health by 33.5% during the third quarter. Evergreen Wealth Management LLC now owns 17,283 shares of the company’s stock worth $5,584,000 after acquiring an additional 4,336 shares during the last quarter. Blume Capital Management Inc. raised its position in shares of Elevance Health by 236.7% during the third quarter. Blume Capital Management Inc. now owns 6,145 shares of the company’s stock worth $1,986,000 after acquiring an additional 4,320 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of Elevance Health by 31.1% during the third quarter. Victory Capital Management Inc. now owns 461,693 shares of the company’s stock valued at $149,182,000 after acquiring an additional 109,462 shares during the period. Finally, Caprock Group LLC acquired a new position in shares of Elevance Health during the third quarter valued at $1,638,000. Institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Down 0.7%

NYSE:ELV opened at $396.81 on Friday. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $412.96. The business’s 50-day moving average price is $320.85 and its two-hundred day moving average price is $333.61. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $86.17 billion, a price-to-earnings ratio of 16.88, a PEG ratio of 2.27 and a beta of 0.66.

Elevance Health (NYSE:ELV – Get Free Report) last posted its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $1.84. The company had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period in the previous year, the company earned $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities analysts expect that Elevance Health, Inc. will post 26.79 earnings per share for the current year.

Elevance Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. Elevance Health’s payout ratio is currently 29.26%.

Wall Street Analysts Forecast Growth

ELV has been the subject of a number of research reports. Barclays lifted their price objective on Elevance Health from $393.00 to $408.00 and gave the stock an “overweight” rating in a research report on Friday, April 24th. Leerink Partners set a $364.00 target price on shares of Elevance Health in a research report on Thursday, April 23rd. Evercore raised their target price on shares of Elevance Health from $345.00 to $360.00 in a research note on Thursday, April 23rd. Robert W. Baird lifted their price target on shares of Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research report on Thursday, April 23rd. Finally, Bank of America raised shares of Elevance Health from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $405.00 to $435.00 in a research note on Wednesday, April 29th. Thirteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $384.58.

View Our Latest Report on Elevance Health

Elevance Health Profile

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.